The Oncologist

12/12/2025

Identity matters! Patients with instead of had reduced cost, ambulatory use with dramatic difference (10.2 vs 30.7 mo) despite similar tolerance of . Reflexive genomic testing at diagnosis may improve outcomes

AbstractBackground. There is limited evidence regarding the economic burden, treatment patterns, and overall survival (OS) of patients with cholangiocarcin

12/11/2025

Imatinib-associated severe skin rash poses a challenge in the management of gastrointestinal stromal tumors. This study demonstrates that personalized desensitization therapy assisted with therapeutic drug monitoring effectively enables most patients to resume imatinib.

AbstractBackground. Skin rash is one of the most common imatinib-associated adverse events in patients with gastrointestinal stromal tumors (GISTs), potent

12/09/2025

This study reveals key clinical patterns & risk factors (CNS/bone marrow involvement, ↑creatinine) in rare intravascular large B-cell lymphoma. Early diagnosis & CD20-based therapy may improve outcomes.
https://doi.org/10.1093/oncolo/oyaf156

12/08/2025

ICIs-induced SJS/TEN-like reactions show 21% mortality. Fatal cases have shorter latency (30.3 days) and severe mucosal involvement. Systemic glucocorticoids are critical; antibiotics show promise.

AbstractBackground. Immune checkpoint inhibitors (ICIs) have demonstrated significant therapeutic benefits but are also associated with skin-related advers

12/05/2025

Differential of mediastinal masses: if you are smart, you do not forget SMARCA4! This case-based review illustrates diagnostic challenges, biology, molecular features and treatment implications of key novel entities, such as SMARCA4-deficient undifferentiated tumor.
https://doi.org/10.1093/oncolo/oyaf121

12/04/2025

This study highlights the barriers hindering adherence to the recommended follow-up visit after treatment of a suspicious cervical lesion. Solutions to barriers are necessary to ensure quality cervical screening in Tanzania.
https://doi.org/10.1093/oncolo/oyaf111

12/03/2025

Prediction models can help investigators select patients with low TMB for immunotherapy treatments.

AbstractBackground. Immune checkpoint inhibitors (ICIs) have significantly advanced cancer therapy, yet their efficacy in tumors with low tumor mutational

12/02/2025

That ASXL1 mutation you found in NGS from the prostate? CH being picked up. Implications here...

AbstractBackground. Clonal hematopoiesis (CH) may be inferred from clinical next-generation sequencing (NGS) of tumor tissue. The clinical significance of

12/01/2025

REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens
https://doi.org/10.1093/oncolo/oyaf135

11/26/2025

Advocacy can improve the lives of our survivors and the health of our community. We can do more to support them.

AbstractPurpose. This study aimed to evaluate the facilitators and barriers to self-advocacy and advocacy in the community of cervical and breast cancer su

11/25/2025

KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape

https://doi.org/10.1093/oncolo/oyaf153

11/24/2025

Overcoming resistance to sotorasib in KRAS G12C-mutant NSCLC: Dose re-escalation restores tumor response, advancing personalized cancer care.
https://doi.org/10.1093/oncolo/oyaf030